The Digital Pathology AI Landscape
AI-powered diagnostic tools are reshaping anatomic pathology, enabling faster, more consistent analysis of tissue samples at scale. The market for AI in pathology reached approximately $107 million in 2025 and is projected to grow at a 26.5% CAGR through 2030, driven by increasing FDA clearances and health system adoption.
Regulatory Milestones Accelerating Adoption
The pace of regulatory clearances has accelerated significantly since Paige secured the first FDA approval for an AI pathology product in 2021. Key recent clearances include:
| Company | Product | Clearance | Year |
|---|---|---|---|
| Paige | Paige Prostate | FDA De Novo | 2021 |
| Proscia | Concentriq AP-Dx | FDA 510(k) | 2024 |
| PathAI | AISight Dx | FDA 510(k) | 2025 |
| Ibex | Prostate Detect | FDA 510(k) | 2025 |
| Indica Labs | HALO AP Dx | FDA 510(k) | 2025 |
Clinical Application Areas
Most commercially available AI models target oncology, particularly prostate cancer and breast cancer detection, where large annotated datasets and clear clinical need have driven development. Emerging applications include gastric cancer, colorectal polyp classification, and non-alcoholic steatohepatitis (NASH/MASH) scoring for clinical trials.
Key Buying Considerations
- Regulatory pathway
- FDA-cleared products can be used for primary diagnosis; CE-IVD products are approved in EU/EEA; Research Use Only (RUO) tools cannot support clinical decisions.
- Scanner integration
- AI platforms must be validated with specific whole-slide imaging scanners. Compatibility with your existing hardware is critical.
- Deployment model
- Cloud-based platforms offer scalability; on-premises deployments address data sovereignty requirements common in healthcare.
- Workflow integration
- Seamless LIS/LIMS connectivity and DICOM compatibility minimize disruption to existing laboratory operations.
Market Structure
Over 30 vendors now offer more than 100 commercial AI products for digital pathology, spanning CE-IVDR, FDA, and RUO categories. The sector has attracted approximately $2 billion in venture investment across 60+ funding rounds, with PathAI (~$240M) and Paige (~$241M) among the most heavily funded companies prior to Paige's acquisition by Tempus AI.